<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="563fecaf-128d-4f6b-81c8-715b4d90a261"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM INJECTION safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM INJECTION<br/>LEVOTHYROXINE SODIUM injection, for intravenous use<br/>Initial U.S. Approval: 1969</title>
   <effectiveTime value="20240710"/>
   <setId root="6279390b-ee61-4ef9-ac15-25537ca783c1"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118707839" root="1.3.6.1.4.1.519.1"/>
            <name>Hikma Pharmaceuticals USA Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="946499746" root="1.3.6.1.4.1.519.1"/>
                  <name>Hikma Pharmaceuticals USA Inc.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f69542ce-ce1d-4ca5-9641-77138284afa9"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20240710"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="24201-002" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEVOTHYROXINE SODIUM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="ug" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOTHYROXINE SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOTHYROXINE SODIUM</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2PP9364507" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BETADEX SULFOBUTYL ETHER SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="24201-002-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20221115"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA214253" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_867ac517-e81c-460a-a3e0-9555880c95ca">
               <id root="a07c3eb1-67bc-4019-89b0-af3c6c15e3d1"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Thyroid hormones, including Levothyroxine Sodium Injection, should not be used for the treatment of obesity or for weight loss. (<linkHtml href="#LINK_db785339-3605-4cf8-9d49-7ac690fdfcd3">5.3</linkHtml>)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Larger doses may produce serious or even life-threatening manifestations of toxicity. (<linkHtml href="#LINK_db0b40ff-eda0-4023-9c87-c25673faafd1">6</linkHtml>)</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS </paragraph>
                        <paragraph>
                           <content styleCode="bold">Thyroid hormones, including Levothyroxine Sodium Injection, should not be used for the treatment of obesity or for weight loss. (<linkHtml href="#LINK_db785339-3605-4cf8-9d49-7ac690fdfcd3">5.3</linkHtml>) Larger doses may produce serious or even life-threatening manifestations of toxicity. (<linkHtml href="#LINK_db0b40ff-eda0-4023-9c87-c25673faafd1">6</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_3a5f2db1-7be5-45cf-abf2-388bc5f08ace">
               <id root="fe33d372-daae-4937-ad8a-7f49253031ba"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>: The relative bioavailability between Levothyroxine Sodium Injection and oral levothyroxine products has not been established.  Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium Injection as accurate dosing conversion has not been studied.</paragraph>
               </text>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levothyroxine Sodium is an L-thyroxine product. Levothyroxine (T<sub>4</sub>) Sodium Injection is indicated for the treatment of myxedema coma. (<linkHtml href="#LINK_3a5f2db1-7be5-45cf-abf2-388bc5f08ace">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">Important Limitations of Use:</content>
                        </paragraph>
                        <paragraph>The relative bioavailability of this drug has not been established. Use caution when converting patients from oral to intravenous levothyroxine. (<linkHtml href="#LINK_3a5f2db1-7be5-45cf-abf2-388bc5f08ace">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8a18a944-0587-4a25-9dcf-030e108bb313">
               <id root="64a1a859-c071-436b-a163-ec117e63a96a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Consider the patient’s age, general physical condition, cardiac risk factors, as well as the clinical severity of myxedema and duration of myxedema symptoms when determining dosages of Levothyroxine Sodium Injection. (<linkHtml href="#LINK_a42d4caf-0281-43f7-8a1c-cb7d29472289">2.1</linkHtml>)</item>
                           <item>Start with lower doses in elderly patients and in patients with underlying cardiovascular disease. (<linkHtml href="#LINK_a42d4caf-0281-43f7-8a1c-cb7d29472289">2.1</linkHtml>)</item>
                           <item>An initial intravenous loading dose of Levothyroxine Sodium Injection between 300 to 500 mcg followed by once daily intravenous maintenance doses between 50 and 100 mcg should be administered, as clinically indicated, until the patient can tolerate oral therapy.  (<linkHtml href="#LINK_a42d4caf-0281-43f7-8a1c-cb7d29472289">2.1</linkHtml>)</item>
                           <item>Do not add to other IV fluids. (<linkHtml href="#LINK_a42d4caf-0281-43f7-8a1c-cb7d29472289">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a42d4caf-0281-43f7-8a1c-cb7d29472289">
                     <id root="db7bef99-75a2-42ff-b30b-b0ab9f3be270"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Dosage</title>
                     <text>
                        <paragraph>An initial intravenous loading dose of Levothyroxine Sodium Injection between 300 to 500 mcg, followed by once daily intravenous maintenance doses between 50 and 100 mcg, should be administered, as clinically indicated, until the patient can tolerate oral therapy.  </paragraph>
                        <paragraph>The age, general physical condition, and cardiac risk factors of the patient, as well as the clinical severity of myxedema and duration of myxedema symptoms should be considered when determining the starting and maintenance dosages of Levothyroxine Sodium Injection.</paragraph>
                        <paragraph>Levothyroxine Sodium Injection produces a gradual increase in the circulating concentrations of the hormone with an approximate half-life of 9 to 10 days in hypothyroid patients.  Daily administration of Levothyroxine Sodium Injection should be maintained until the patient is capable of tolerating an oral dose and is clinically stable.  For chronic treatment of hypothyroidism, an oral dosage form of levothyroxine should be used to maintain a euthyroid state.  Relative bioavailability between Levothyroxine Sodium Injection and oral levothyroxine products has not been established.  Based on medical practice, the relative bioavailability between oral and intravenous administration of Levothyroxine Sodium Injection is estimated to be from 48 to 74%.  Due to differences in absorption characteristics of patients and the oral levothyroxine product formulations, TSH and thyroid hormone levels should be measured a few weeks after initiating oral levothyroxine and dose adjusted accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_64a93a10-fd98-478b-83d1-fae96d989673">
                     <id root="af648c8e-c0b8-40d7-9b46-e416544622bc"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Dosing in the Elderly and in Patients with Cardiovascular Disease</title>
                     <text>
                        <paragraph>Intravenous levothyroxine may be associated with cardiac toxicity – including arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death – in the elderly and in those with underlying cardiovascular disease. Therefore, cautious use, including doses in the lower end of the recommended range, may be warranted in these populations.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_797d48a1-2374-4a5c-b862-7ab37d385329">
                     <id root="c68b0f4e-f030-46b6-9e98-3b4436403db8"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.3 Administration Instructions</title>
                     <text>
                        <paragraph>Intravenous levothyroxine may be associated with cardiac toxicity-including arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death—in the elderly and in those with underlying cardiovascular disease. Therefore, cautious use, including doses in the lower end of the recommended range, may be warranted in these populations.</paragraph>
                        <paragraph>Discard any unused portion. DO NOT ADD LEVOTHYROXINE SODIUM INJECTION TO OTHER INTRAVENOUS FLUIDS. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4ad350b9-662d-4514-8d25-2f4118abb98a">
               <id root="e97a57fc-594f-4f21-88fc-e8d76e061409"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Levothyroxine sodium injection 100 mcg/mL is a clear, colorless to slightly yellow solution supplied as 1 mL per vial.</paragraph>
               </text>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 100 mcg/mL in a single-dose vial. Ready-to-use solution. (<linkHtml href="#LINK_4ad350b9-662d-4514-8d25-2f4118abb98a">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_11e23a11-42ba-4ac5-aa5b-9a594d7999fb">
               <id root="e8c329fc-8a26-4a3d-a410-41027f8db24c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_24a3a103-b9c5-427b-881e-671b6d11a9b9">
               <id root="9bffa48b-678b-4d69-8bcf-bd2159c5fbd0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease:</content> Overtreatment may cause arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death, particularly in patients with cardiovascular disease and in elderly patients. Start with lower doses in elderly patients and in patients with underlying cardiovascular disease and monitor patients after administration (<linkHtml href="#LINK_d538d59b-fe95-43c1-95e7-2e94ddf5569a">5.1</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency </content>Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment (<linkHtml href="#LINK_0708831d-0939-42ea-81dd-70ed21a58141">5.2</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Worsening of Diabetic Control</content>: May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control (<linkHtml href="#LINK_db785339-3605-4cf8-9d49-7ac690fdfcd3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d538d59b-fe95-43c1-95e7-2e94ddf5569a">
                     <id root="2c7ed29f-c054-4b99-9722-72a04f74f1e7"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.1 Risk of Cardiac Complications in Elderly and in Patients with Cardiovascular Disease</title>
                     <text>
                        <paragraph>Excessive bolus dosing of Levothyroxine Sodium Injection (greater than 500 mcg) is associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition.  Adverse events that can potentially be related to the administration of large doses of Levothyroxine Sodium Injection include arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death.  Cautious use, including doses in the lower end of the recommended range, may be warranted in these populations.  Close observation of the patient following the administration of Levothyroxine Sodium Injection is advised.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0708831d-0939-42ea-81dd-70ed21a58141">
                     <id root="d54ceb7c-69f3-486c-8712-c21d7fee7106"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.2 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency</title>
                     <text>
                        <paragraph>Chronic autoimmune thyroiditis, which can lead to myxedema coma, may occur in association with other autoimmune disorders such as adrenal insufficiency, pernicious anemia, and insulin‑dependent diabetes mellitus. Patients should be treated with replacement glucocorticoids prior to initiation of treatment with Levothyroxine Sodium Injection, until adrenal function has been adequately assessed.  Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone.  With initiation of Levothyroxine Sodium Injection, patients with myxedema coma should also be monitored for previously undiagnosed diabetes insipidus.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_db785339-3605-4cf8-9d49-7ac690fdfcd3">
                     <id root="c257cffb-7025-4ba1-ad9f-c2edefd2aced"/>
                     <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
                     <title>5.3 Worsening of Diabetic Control</title>
                     <text>
                        <paragraph>Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control <content styleCode="italics">[see Drug Interactions (7.1)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_db0b40ff-eda0-4023-9c87-c25673faafd1">
               <id root="fb29cd26-61c7-4c92-b464-8c5acb3b3c1f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions associated with levothyroxine are primarily those of hyperthyroidism due to therapeutic overdosage <content styleCode="italics">[see <content styleCode="underline">
                           <linkHtml href="#LINK_24a3a103-b9c5-427b-881e-671b6d11a9b9">Warnings and Precautions (5)</linkHtml>
                        </content>, <content styleCode="underline">
                           <linkHtml href="#LINK_dbe4d68d-8360-4e8e-9c51-3a000b04bd41">Overdosage (10)</linkHtml>
                        </content>]</content>. They include the following:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="italics">General:</content> fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating</item>
                     <item>
                        <content styleCode="italics">Central nervous system:</content> headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia</item>
                     <item>
                        <content styleCode="italics">Musculoskeletal:</content> tremors, muscle weakness, muscle spasm</item>
                     <item>
                        <content styleCode="italics">Cardiovascular:</content> palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest</item>
                     <item>
                        <content styleCode="italics">Respiratory:</content> dyspnea</item>
                     <item>
                        <content styleCode="italics">Gastrointestinal:</content> diarrhea, vomiting, abdominal cramps, elevations in liver function tests</item>
                     <item>
                        <content styleCode="italics">Dermatologic:</content> flushing, rash</item>
                  </list>
                  <paragraph>Seizures have been reported rarely with the institution of levothyroxine therapy.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.</paragraph>
               </text>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions associated with Levothyroxine Sodium Injection are primarily those of hyperthyroidism due to therapeutic overdosage: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia, tremors, muscle weakness, muscle spasm, palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest, dyspnea, diarrhea, vomiting, abdominal cramps, elevations in liver function tests, flushing, and rash. (<linkHtml href="#LINK_db0b40ff-eda0-4023-9c87-c25673faafd1">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hikma at us.hikma@primevigilance.com or call 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_27dc31d2-6ac8-43b6-a845-7f078595f4bd">
               <id root="ea6117b4-2f56-43df-aa84-86170a45f7cf"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Injection. (<linkHtml href="#LINK_27dc31d2-6ac8-43b6-a845-7f078595f4bd">7</linkHtml>, <linkHtml href="#LINK_fafaceb0-3d17-4bb7-bcf0-9cab2980e9fc">12.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_90c5a6be-508a-446d-9293-8de77e0e9f15">
                     <id root="1fb58c6a-8af0-464d-aea4-c81c6336b829"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics</title>
                     <text>
                        <paragraph>Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Injection (see Tables 1-3).</paragraph>
                        <table>
                           <caption>Table 1: Drugs That May Alter T<sub>4</sub> and Triiodothyronine (T<sub>3</sub>) Serum Transport Without Effecting Free Thyroxine (FT<sub>4</sub>) Concentration (Euthyroidism)</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clofibrate</paragraph>
                                    <paragraph>Estrogen-containing oral contraceptives</paragraph>
                                    <paragraph>Estrogens (oral)</paragraph>
                                    <paragraph>Heroin/Methadone</paragraph>
                                    <paragraph>5-Fluorouracil</paragraph>
                                    <paragraph>Mitotane</paragraph>
                                    <paragraph>Tamoxifen</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <paragraph>These drugs may increase serum thyroxine-binding globulin (TBG) concentration.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Androgens/Anabolic Steroids</paragraph>
                                    <paragraph>Asparaginase</paragraph>
                                    <paragraph>Glucocorticoids</paragraph>
                                    <paragraph>Slow-Release Nictonic Acid</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <paragraph>These drugs may decrease serum TBG concentration.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Potential impact (below): Administration of these agents with levothyroxine results in an initial transient increase in FT<sub>4</sub>. Continued administration results in a decrease in serum T<sub>4</sub> and normal FT<sub>4</sub> and TSH concentrations.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Salicylates (&gt; 2 g/day)<br/>
                                       <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <paragraph>Salicylates inhibit binding of T<sub>4</sub> and T<sub>3</sub> to TBG and transthyretin. An initial increase in serum FT<sub>4</sub> is followed by return of FT<sub>4</sub> to normal levels with sustained therapeutic serum salicylate concentrations, although total T<sub>4</sub> levels may decrease by as much as 30%.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Other drugs:</paragraph>
                                    <paragraph>Carbamazepine</paragraph>
                                    <paragraph>Furosemide (&gt; 80 mg IV)</paragraph>
                                    <paragraph>Heparin</paragraph>
                                    <paragraph>Hydantoins</paragraph>
                                    <paragraph>Non-Steroidal Anti-Inflammatory Drugs</paragraph>
                                    <paragraph>-    Fenamates</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <paragraph>These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table>
                           <caption>Table 2: Drugs That May Alter Hepatic Metabolism of T<sub>4</sub> (Hypothyroidism)</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Phenobarbital<br/>Rifampin</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <paragraph>Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table>
                           <caption>Table 3: Drugs That May Decrease Conversion of T<sub>4</sub> to T<sub>3</sub>
                           </caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T<sub>4</sub> to T<sub>3</sub>, leading to decreased T<sub>3</sub> levels. However, serum T<sub>4</sub> levels are usually normal but may occasionally be slightly increased.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Beta-adrenergic antagonists</paragraph>
                                    <paragraph>e.g., Propranolol &gt; 160 mg/day)<br/>
                                       <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Rrule">
                                    <paragraph>In patients treated with large doses of propranolol (&gt; 160 mg/day), T<sub>3</sub> and T<sub>4</sub> levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Glucocorticoids<br/>(e.g., Dexamethasone ≥ 4 mg/day)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Rrule">
                                    <paragraph>Short-term administration of large doses of glucocorticoids may decrease serum T<sub>3</sub> concentrations by 30% with minimal change in serum T<sub>4</sub> levels. However, long-term glucocorticoid therapy may result in slightly decreased T<sub>3</sub> and T<sub>4</sub> levels due to decreased TBG production (See above).</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Other drugs:<br/>Amiodarone</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Rrule">
                                    <paragraph>Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c2222628-d63c-40f6-bc47-d14fc0ce055e">
                     <id root="bb67d25f-5bb8-43cd-a9c3-8fa32e5e8b92"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.2 Antidiabetic Therapy</title>
                     <text>
                        <paragraph>Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements.  Careful monitoring of diabetic control is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_493fe719-506d-49aa-a7be-81181eda1bc9">
                     <id root="34359e45-0ae7-482c-a571-1e34f6e823e8"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.3 Oral Anticoagulants</title>
                     <text>
                        <paragraph>Levothyroxine increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_22a7bdab-91b2-42f7-a6d6-bbd105492837">
                     <id root="abac870c-7e1f-4437-937a-fc4ba9a61512"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.4 Digitalis Glycosides</title>
                     <text>
                        <paragraph>Levothyroxine may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7380b23e-0e8e-419b-ad3c-e27be7a611e4">
                     <id root="6dbcd55b-09b7-4174-b977-048e5734e947"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.5 Antidepressant Therapy</title>
                     <text>
                        <paragraph>Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Levothyroxine may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_54e1ce5b-d2c7-4771-b3f6-4774fdca51ab">
                     <id root="b04ce72e-a7cd-4ead-8670-c8a3bdf2ae66"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.6 Ketamine</title>
                     <text>
                        <paragraph>Concurrent use of ketamine and levothyroxine may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e4db5ce5-0d55-48a4-88d3-879e680461ee">
                     <id root="a6e67252-e7d7-4848-89d6-39a7f81f9dd3"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.7 Sympathomimetics</title>
                     <text>
                        <paragraph>Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_47205ca9-ac86-4098-98e7-597175368570">
                     <id root="4247ad25-781f-41dc-b10d-d9c9638a8578"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>7.8 Drug-Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_05d005b2-3be5-4855-9024-fd57d79e746b">
               <id root="c33c8a1b-4853-4c65-bc03-4c495398cbae"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20240710"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Elderly and those with underlying cardiovascular disease should receive doses at the lower end of the recommended range. (<linkHtml href="#LINK_b58e8022-8cb2-4a49-b982-0d674f62e000">8.5</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_75316fec-2398-4676-b5c9-af9db95fd81d">
                     <id root="747689a6-4215-4f0e-bb1a-bf379ca67af0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The clinical data in pregnant women treated with oral levothyroxine to treat hypothyroidism do not indicate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are no data available on the use of Levothyroxine Sodium Injection in pregnant women. There are risks to the mother and fetus associated with myxedema coma in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>.</paragraph>
                        <paragraph>No developmental or reproductive toxicity studies in animals have been conducted with Levothyroxine Sodium Injection.</paragraph>
                        <paragraph>The estimated background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have background risks of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                        </paragraph>
                        <paragraph>Myxedema coma is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with myxedema coma increases the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for pregnant women with myxedema coma should not be withheld due to potential concerns regarding the effects of Levothyroxine Sodium Injection on the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b98266a2-e702-435b-8cdf-b1caad7738a9">
                     <id root="ed29c7c6-2319-458e-86ee-4790bc92cf9f"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported, and there is no information on the effects of levothyroxine on milk production from levothyroxine oral treatment. There are no available data with use of Levothyroxine Sodium Injection in lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Levothyroxine Sodium Injection and any potential adverse effects on the breastfed infant from Levothyroxine Sodium Injection or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f3f8b2cc-35e3-48c5-ac12-e8e17e82d0cb">
                     <id root="694f1dde-32b1-4d5b-a3c6-3c07ab127333"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of Levothyroxine Sodium Injection have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b58e8022-8cb2-4a49-b982-0d674f62e000">
                     <id root="15263320-7773-4356-b1b6-3aa4ecac4d57"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.5 Geriatric Use and Patients with Underlying Cardiovascular Disease</title>
                     <text>
                        <paragraph>See Section 2, Dosage and Administration, for full prescribing information in the geriatric patient population. Because of the increased prevalence of cardiovascular disease in the elderly, cautious use of Levothyroxine Sodium Injection in the elderly and in patients with known cardiac risk factors is advised. Atrial fibrillation is a common side effect associated with levothyroxine treatment in the elderly <content styleCode="italics">[see <linkHtml href="#LINK_8a18a944-0587-4a25-9dcf-030e108bb313">Dosage and Administration (2)</linkHtml> and <linkHtml href="#LINK_24a3a103-b9c5-427b-881e-671b6d11a9b9">Warnings and Precautions (5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_01e013a1-2425-416a-bbbd-1f985ae79b37">
                     <id root="4553a94e-f6a6-4eaa-a74e-c86cb47bde2e"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Serum creatinine and levothyroxine levels should be closely monitored in patients with severe renal impairment receiving intravenous levothyroxine with betadex sulfobutyl (SBECD) <content styleCode="italics">[See <linkHtml href="#LINK_fafaceb0-3d17-4bb7-bcf0-9cab2980e9fc">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_dbe4d68d-8360-4e8e-9c51-3a000b04bd41">
               <id root="a25d2547-4c0e-4e82-8823-80e23346479f"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In general, the signs and symptoms of overdosage with levothyroxine are those of hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (5) and Adverse Reactions (6)].</content> In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Excessive doses of Levothyroxine Sodium Injection (greater than 500 mcg) are associated with cardiac complications in patients with underlying cardiac disease.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Treatment of Overdosage</content>
                  </paragraph>
                  <paragraph>Levothyroxine Sodium Injection should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur. To obtain up-to-date information about the treatment of overdose, a good resource is the certified Regional Poison Control Center. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.</paragraph>
                  <paragraph>In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s medical status.</paragraph>
               </text>
               <effectiveTime value="20240710"/>
            </section>
         </component>
         <component>
            <section ID="LINK_ee4472bc-5546-4dd2-836a-32d31b5f4aca">
               <id root="6fa4f815-eee9-4b6f-91de-cd4302055c8f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Levothyroxine sodium injection contains synthetic levothyroxine (L-thyroxine) sodium salt.  Levothyroxine sodium has an empirical formula of C<sub>15</sub>H<sub>10</sub>I<sub>4</sub>NNaO<sub>4</sub>, a molecular weight of 798.85 g/mol (anhydrous), and the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Levothyroxine sodium injection is a sterile, preservative-free, clear, colorless to slightly yellow solution for intravenous administration available as 100 mcg/mL in a single-dose clear glass vial. Each mL of levothyroxine sodium injection also contains 0.05 mg arginine, USP; 80 mg betadex sulfobutyl ether sodium, USP; 0.05 mg edetate disodium, USP; and water for injection, USP. Sodium chloride, USP was added to adjust tonicity. Hydrochloric acid, NF and/or sodium hydroxide, NF may have been added for pH adjustment.</paragraph>
               </text>
               <effectiveTime value="20240710"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="levothyroxine-sodium-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_99c9d4bc-1ce9-4693-a45d-6d6d954b7c40">
               <id root="4ee4977c-8b00-4317-a858-0741a350ec40"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20240710"/>
               <component>
                  <section ID="LINK_40989ef6-ef5c-4518-b40b-fee7b4862467">
                     <id root="d075ee36-5cbc-40a8-9afc-48bf5919dcda"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.  Triiodothyronine (T<sub>3</sub>) and levothyroxine (T<sub>4</sub>) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA.  This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. </paragraph>
                        <paragraph>The physiological actions of thyroid hormones are produced predominantly by T<sub>3</sub>, the majority of which (approximately 80%) is derived from T<sub>4</sub> by deiodination in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6ba990cf-132a-4568-beb0-69d5014d0ddd">
                     <id root="87050a47-6749-488a-84ee-45d3d8e1ac16"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Thyroid hormone synthesis and secretion is regulated by the hypothalamic pituitary-thyroid axis.  Thyrotropin releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin stimulating hormone (TSH) from the anterior pituitary.  TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, T<sub>4</sub> and T<sub>3</sub>, by the thyroid gland.  Circulating serum T<sub>3</sub> and T<sub>4</sub> levels exert a feedback effect on both TRH and TSH secretion.  When serum T<sub>3</sub> and T<sub>4</sub> levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion increases.  TSH is used for the diagnosis of hypothyroidism and evaluation of levothyroxine therapy adequacy with other laboratory and clinical data <content styleCode="italics">[see <linkHtml href="#LINK_a42d4caf-0281-43f7-8a1c-cb7d29472289">Dosage (2.1)</linkHtml>]. </content>  There are drugs known to affect thyroid hormones and TSH by various mechanisms and those examples are diazepam, ethioamide, lovastatin, metoclopramide, 6-mercaptopurine, nitroprusside, perphenazine, and thiazide diuretics.  Some drugs may cause a transient decrease in TSH secretion without hypothyroidism and those drugs (dose) are dopamine (greater than 1 mcg per kg per min), glucocorticoids (hydrocortisone greater than 100 mg per day or equivalent) and octreotide (greater than 100 mcg per day). </paragraph>
                        <paragraph>Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone.  The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids.  The protein anabolic effects of thyroid hormones are essential to normal growth and development.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fafaceb0-3d17-4bb7-bcf0-9cab2980e9fc">
                     <id root="d55a7ff4-831b-4536-a10a-6c74ebb0145f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Absorption </content>– Levothyroxine Sodium Injection is administered via the intravenous route.  Following administration, the synthetic levothyroxine cannot be distinguished from the natural hormone that is secreted endogenously. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution –</content> Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine binding globulin (TBG), thyroxine binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone.  The higher affinity of both TBG and TBPA for T<sub>4</sub> partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T<sub>4</sub> compared to T<sub>3</sub>.  Protein bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone.  Only unbound hormone is metabolically active.  Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins <content styleCode="italics">[see <linkHtml href="#LINK_24a3a103-b9c5-427b-881e-671b6d11a9b9">Warnings and Precautions (5)</linkHtml> and <linkHtml href="#LINK_27dc31d2-6ac8-43b6-a845-7f078595f4bd">Drug Interactions (7)</linkHtml>].</content>   Thyroid hormones do not readily cross the placental barrier <content styleCode="italics">[see <linkHtml href="#LINK_24a3a103-b9c5-427b-881e-671b6d11a9b9">Warnings and Precautions (5)</linkHtml> and <linkHtml href="#LINK_05d005b2-3be5-4855-9024-fd57d79e746b">Use in Specific Populations (8)</linkHtml>].</content> Betadex sulfobutyl ether (SBECD) does not affect levothyroxine binding to plasma proteins.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism </content>– T<sub>4</sub> is slowly eliminated.  The major pathway of thyroid hormone metabolism is through sequential deiodination.  Approximately eighty percent of circulating T<sub>3</sub> is derived from peripheral T<sub>4</sub> by mono-deiodination.  The liver is the major site of degradation for both T<sub>4</sub> and T<sub>3</sub>, with T<sub>4</sub> deiodination also occurring at a number of additional sites, including the kidney and other tissues.  Approximately 80% of the daily dose of T<sub>4</sub> is deiodinated to yield equal amounts of T<sub>3</sub> and reverse T<sub>3</sub> (rT<sub>3</sub>).  T<sub>3</sub> and rT<sub>3</sub> are further deiodinated to diiodothyronine.  Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Elimination </content>– Thyroid hormones are primarily eliminated by the kidneys.  A portion of the conjugated hormone reaches the colon unchanged, where it is hydrolyzed and eliminated in feces as the free hormones.  Urinary excretion of T<sub>4</sub> decreases with age.</paragraph>
                        <paragraph>In patients with severe renal impairment or ESRD (eGFR of &lt; 15 mL/min/1.73 m2), accumulation of SBECD occurs [see <content styleCode="italics">
                              <linkHtml href="#LINK_01e013a1-2425-416a-bbbd-1f985ae79b37">Renal Impairment 8.6</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1:</content> Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients</paragraph>
                        <table>
                           <col width="13%"/>
                           <col width="32%"/>
                           <col width="16%"/>
                           <col width="19%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Hormone</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Ratio in Thyroglobulin</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Biologic Potency</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Half-Life (Days)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Protein Binding </content>
                                       <br/>
                                       <content styleCode="bold">(%)<sup>2</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>T<sub>4</sub>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>10 to 20</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6 to 8<sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>99.96</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>T<sub>3</sub>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>99.5</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>T<sub>4</sub>:  Levothyroxine</paragraph>
                        <paragraph>T<sub>3</sub>:  Liothyronine <br/>
                           <sup>1</sup>3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism. <br/>
                           <sup>2</sup>Includes TBG, TBPA, and TBA.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_516ae387-11d4-4520-9197-889a1e3a1a9c">
               <id root="d950cebf-5883-4855-9ccf-5455aa60209a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20240710"/>
               <component>
                  <section ID="LINK_12d8bbc0-cb53-41ce-9302-8d902eb7dbda">
                     <id root="da06ec3e-9f68-4462-8185-7c05a5408e16"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of Levothyroxine Sodium Injection.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5b472b45-c6b3-4993-a55d-993607f7484c">
                     <id root="0e4c6420-b6f5-420d-946b-96fa624ac282"/>
                     <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and Pharmacology</title>
                     <text>
                        <paragraph>No animal toxicology studies have been conducted with Levothyroxine Sodium Injection.</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c8ca556f-69e4-47d9-a3ac-298121a446a3">
               <id root="c9092a9f-aeb5-4093-a806-0ca787aa4af6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>No clinical studies have been conducted with Levothyroxine Sodium Injection in patients with myxedema coma.  However, data from published literature support the intravenous use of levothyroxine sodium for the treatment of myxedema coma.</paragraph>
               </text>
               <effectiveTime value="20240710"/>
            </section>
         </component>
         <component>
            <section ID="LINK_2dc23021-6bbe-42dd-ad8a-0be911cec6ac">
               <id root="c0504f8c-9228-4624-b817-f00a7527eb20"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text/>
               <effectiveTime value="20240710"/>
               <component>
                  <section ID="LINK_d93d60f3-a629-47df-be49-d4bf668462e4">
                     <id root="e8640caf-fe6e-45c6-b336-6bd4654c4d73"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Levothyroxine Sodium Injection 100 mcg/mL is a clear, colorless to slightly yellow solution, supplied as1 mL per vial.</paragraph>
                        <paragraph>Package of 1 single-dose vial: NDC 24201-002-01</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c830c8d3-0baa-4ade-b833-2d44231b35ed">
                     <id root="89f74a35-6fde-4312-9724-e9df8c469051"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Protect from light and store product at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Drug product is preservative free.  Discard any unused portion.</paragraph>
                        <paragraph>Manufactured for:</paragraph>
                        <paragraph>Hikma Pharmaceuticals USA Inc.</paragraph>
                        <paragraph>Berkeley Heights, NJ 07922</paragraph>
                        <paragraph>www.hikma.com/us</paragraph>
                        <paragraph>Revised: 07/2024</paragraph>
                        <paragraph>462-046-00</paragraph>
                     </text>
                     <effectiveTime value="20240710"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_570efc59-5f8d-4494-bd0b-1382818c5008">
               <id root="153b7359-cfc4-417d-89d9-d19451b6f0cc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 24201-<content styleCode="bold">002</content>-01    <br/>
                     <content styleCode="bold">Levothyroxine </content>
                     <br/>
                     <content styleCode="bold">Sodium Injection</content>
                     <br/>
                     <content styleCode="bold">100 mcg/mL</content>
                  </paragraph>
                  <paragraph>For Intravenous Use <br/>
1 mL Single-Dose Vial</paragraph>
                  <paragraph>Discard any unused portion. <br/>
Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20240710"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="levothyroxine-sodium-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>